Aclaris Therapeutics (ACRS) Receivables (2017 - 2025)
Aclaris Therapeutics (ACRS) posted quarterly Receivables of $194000.0 for Q2 2025, down 72.29% year-over-year from $700000.0 in Q2 2024, and down 22.4% quarter-over-quarter from $250000.0 in Q1 2025.
Powered by 
Analysis
Aclaris Therapeutics (ACRS) Receivables (2017 - 2025) Analysis & Trends
Aclaris Therapeutics' Receivables history runs 9 years deep, the most recent figure standing at $194000.0 for Q2 2025.
- In Q2 2025, Receivables fell 72.29% year-over-year to $194000.0; the TTM figure through Jun 2025 stood at $194000.0 (down 72.29% YoY), while the FY2024 annual figure was $318000.0, up 6.71% from the prior year.
- Receivables for Q2 2025 stood at $194000.0, down from $250000.0 in the prior quarter.
- The five-year high for Receivables was $963000.0 in Q2 2021, with the low at $194000.0 in Q2 2025.
- The 5-year median for Receivables is $540500.0 (2022), against an average of $531777.8.
- The sharpest annual moves came in 2024 and 2025: Receivables jumped 62.41% in 2024, then plunged 72.29% in 2025.
- Aclaris Therapeutics' Receivables stood at $647000.0 in 2021, then dropped by 25.19% to $484000.0 in 2022, then plunged by 38.43% to $298000.0 in 2023, then gained by 6.71% to $318000.0 in 2024, then sank by 38.99% to $194000.0 in 2025.
- Business Quant data shows ACRS's Receivables at $194000.0 in Q2 2025, $250000.0 in Q1 2025, and $318000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Aclaris Therapeutics | 878.55 Mn | 878.55 Mn | 1.41 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 318,000.00 |
| Sep 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 325,000.00 |
| Mar 31, 2024 | 373,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 346,000.00 |
| Jun 30, 2023 | 431,000.00 |
| Mar 31, 2023 | 686,000.00 |
| Dec 31, 2022 | 484,000.00 |
| Sep 30, 2022 | 597,000.00 |
| Jun 30, 2022 | 637,000.00 |
| Mar 31, 2022 | 633,000.00 |
| Dec 31, 2021 | 647,000.00 |
| Sep 30, 2021 | 835,000.00 |
| Jun 30, 2021 | 963,000.00 |
| Mar 31, 2021 | 837,000.00 |
| Dec 31, 2020 | 1.07 Mn |
| Sep 30, 2020 | 1.19 Mn |